Locations:
Search IconSearch
April 20, 2020/Cancer/News & Insight

How to Continue Caring for Cancer Patients During the Pandemic

Advice from the leader of Cleveland Clinic Cancer Center

Cleveland-Clinic_Taussig_DuskFacade_FromSouthWest-650×433

In spite of the challenges posed by the novel coronavirus pandemic, it is essential that patients with suspected, newly diagnosed or progressive cancers receive ongoing care.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Cleveland Clinic Cancer Center has continued to provide consultation and treatment during the pandemic, utilizing virtual visits and, when necessary, in-person clinical care with appropriate precautions.

In addition to serving patients in our own healthcare system, the cancer center has connected with oncologists in regions hard-hit by COVID-19 who have had to defer or delay cancer treatments, to offer temporary care until conditions improve and patients can resume seeing their own physicians. (Oncologists in need of this assistance should call Cleveland Clinic’s Cancer Answer Line, 866.223.8100.)

How is it possible to maintain patient services during this difficult time? The key is taking care of the cancer center’s workforce so they can care for others, says Cleveland Clinic Taussig Cancer Institute Chair Brian J. Bolwell, MD. That means addressing fears, sharing information regularly and transparently, and providing the support and encouragement people need to do their jobs.

Learn more about Dr. Bolwell’s approach to leading the cancer center and providing care during COVID-19 by reading his latest column in Oncology Times. In addition to heading Cleveland Clinic Cancer Center, Dr. Bolwell is Cleveland Clinic’s Director of Physician Leadership and Development.

Advertisement

Related Articles

Lobular breast cancer cells
December 22, 2025/Cancer/Innovations
Comprehensive Lobular Breast Cancer Program Addresses Often-Misunderstood Disease

Care paths and research initiatives aim to answer unmet clinical needs

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

church bus tour
December 9, 2025/Cancer/News & Insight
Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

Dr. Gerds
December 8, 2025/Cancer/News & Insight
AI Screening Platform Accelerates Trial Recruitment in Polycythemia Vera

AI-driven tools can streamline enrollment and improve efficiency across clinical trials.

Ad